• TLS, STING, and B-Cell Activation in ESCC

  2026-09-11

  A 2025 study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-positive tumor-infiltrating B cells as a central immune population. Its mechanistic work proposes that CD40 and STING compete for TRAF2, reshaping non-canonical NF-κB signaling and promoting IRF4-mediated B-cell activation.

• Ceruletide Workflows for Pancreatic Fibrosis

  2026-09-11

  Ceruletide provides a controllable CCK-receptor stimulus for linking pancreatic injury, stellate-cell activation, and fibrosis biology. This guide translates the ORM2–ZG16 findings into practical sample-handling, assay-design, gastrointestinal physiology, and troubleshooting workflows.

• Disodium bicinchoninate in Cardiac Assays

  2026-09-10

  Disodium bicinchoninate provides an aqueous route for chelation-based assay development, protein normalization, and matrix testing in cell-based cardiac research. This practical workflow connects the reagent’s formulation advantages with high-glucose cardiomyocyte and BMSC experiments while clearly separating reference-study findings from optimization recommendations.

• Fluo-4 AM Maps the AT1R–Ca2+ Axis in Nephropathy

  2026-09-10

  A translational framework for using Fluo-4 AM to interrogate the GPR107–AT1R–Ca2+ pathway in diabetic nephropathy, connect calcium dynamics with collagen type IV remodeling, and improve pharmacological assay decisions.

• Rucaparib: A Mechanism-First Assay Guide

  2026-09-09

  Rucaparib and AG-014699 provide a powerful framework for studying PARP1-dependent DNA repair and radiosensitization. This guide connects repair phenotypes with a recent Pol II cell-death concept to improve assay design and interpretation.

• Viral RIPK3 Degradation and Proteasome-Linked Inflammation

  2026-09-09

  Liu et al. identified a viral inducer of RIPK3 degradation that connects orthopoxvirus immune evasion with SCF-dependent ubiquitination and proteasomal turnover. The study shows that this mechanism changes necroptosis, inflammation, viral replication, and disease severity in genetically defined mouse models.

• Lactate as a Metabolic–Immune Assay Tool

  2026-09-08

  Lactate is more than a glycolytic endpoint: it can connect redox balance, mitochondrial interpretation, hypoxia, and immune regulation. This article presents an assay-centered framework for using L-lactate in metabolic and tumor biology research.

• Angiotensin I: Applied RAS Research Workflows

  2026-09-08

  Angiotensin I supports substrate-to-product studies, ACE activity profiling, cardiovascular disease mechanisms, and controlled neuroendocrine experiments. Its value extends beyond a precursor role: paired with careful peptide handling and orthogonal readouts, it can distinguish renin–angiotensin system regulation from downstream receptor activity and inform antihypertensive drug screening.

• Partial BACE1 Inhibition and Synaptic Function

  2026-09-07

  Satir et al. showed that moderate β-secretase inhibition can reduce amyloid-beta secretion without measurable loss of synaptic transmission in primary rat cortical neurons. The study supports a dose-sensitive strategy for Alzheimer's disease research: target amyloid-beta production inhibition while avoiding exposure levels associated with synaptic dysfunction.

• Mouse Neutrophil Cell Isolation Kit in Immunotherapy

  2026-09-07

  A translational perspective on how controlled, activation-conscious mouse neutrophil preparation can strengthen mechanistic studies of CD300LD-directed mRNA nanovaccines and tumor immunotherapy.

• Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

  2026-09-05

  The 2025 reference study identifies an RXRα/PPARγ/NEDD4 pathway through which berberine suppresses senescence-associated secretory phenotype inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of mouse disease modeling, Smart-seq analysis, cellular assays, and macrophage-specific RXRα knockdown provides a useful framework for connecting nuclear-receptor activity with ubiquitin-dependent control of inflammatory aging.

• Halazone BA1377: Reliable Assay Workflows

  2026-09-04

  A practical, evidence-based guide to using Halazone as a controlled water disinfection agent and neurophysiology reagent without confusing antimicrobial effects with cell viability outcomes. It explains concentration, solubility, storage, carryover controls, and vendor-selection considerations for Halazone SKU BA1377.

• Inside-Out Design of Ternary RNA Nanoparticles

  2026-09-04

  The ACS Nano study shows that polyanion chemistry can control ternary RNA nanoparticle size, core–shell organization, protein interactions, and transfection rather than serving only as a surface-charge modifier. By combining high-throughput stability screening, small-angle neutron scattering, spectroscopy, cell studies, and molecular dynamics, the authors identify design balances that may improve pH-responsive delivery of self-amplifying RNA.

• Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

  2026-09-03

  The 2025 study by Zheng and colleagues identifies an RXRα/PPARγ/NEDD4 pathway through which berberine suppresses SASP-associated inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of mouse disease modeling, foam-cell experiments, Smart-seq profiling, and macrophage-specific RXRα knockdown provides a useful framework for testing nuclear-receptor control of vascular senescence.

• AAV Nanobody Swapping for Precision Tropism

  2026-09-03

  Hoffmann and colleagues identify multiple AAV-DJ capsid hotspots that support nanobody insertion and enable receptor-directed tropism switching, including selective targeting of fibroblast activation protein-positive cancer cells. Their comparison of VP1 and VP2 designs indicates that VP2 insertion can better preserve vector production and infectivity, while combining FAP recognition with heparin-binding ablation reduces off-target infection.

8038 records 1/536 page Next 12345 下5页 Last page